Zentiva rejects Sanofi-Aventis's offer
This article was originally published in Scrip
Executive Summary
Zentiva's board says the acquisition offer made by Sanofi-AventisEurope, a wholly owned subsidiary of Sanofi-Aventis, earlier this month underestimated its value and future prospects. The board recommended Zentiva's shareholders to reject the offer under which its shares were valued at CK1,050 ($71.40) each (Scrip Online, July 15th, 2008).